Enhanced natural killer cell targeting of cancer stem cells using Cetuximab by unknown
POSTER PRESENTATION Open Access
Enhanced natural killer cell targeting of cancer
stem cells using Cetuximab
Steven K Grossenbacher1*, Erik Ames1, Stephanie Mac1, Ragheb Masoud1, Robert J Canter2, Arta M Monjazeb3,
William J Murphy1
From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014
Cancer stem cells (CSCs) are a rare population of cancer
cells which have been shown to be capable of resisting
conventional therapies, such as chemotherapy and radia-
tion. Their persistence following therapeutic intervention,
coupled with their stem like nature, endows these cells
with the ability to repopulate the tumor, leading to even-
tual tumor relapse. Previously, it has been shown that the
effects of Cetuximab antibody therapy, targeting EGFR on
solid tumors, are partially mediated through antibody
dependent cellular cytotoxicity (ADCC). Specifically, nat-
ural killer (NK) cells possessing the Fc receptor CD16 are
important in mediating the anti-tumor effects of EGFR
antibodies. Using flow cytometry, and the ALDEFLUOR
assay system to identify CSCs, we observed that human
pancreatic CSCs express higher levels of EGFR compared
to non-CSCs (88.65 vs. 59.7, p < .01) based on median
fluorescence intensity. Due to the role of NK cells in facili-
tating ADCC-mediated anti-tumor responses, and pre-
vious work by our laboratory showing that human NK
cells can preferentially kill CSCs, we hypothesized that fol-
lowing Cetuximab treatment NK cells could mount a
potent cytotoxic response against Cetuximab-bound
CSCs. In vitro ADCC assays revealed that freshly isolated
NK cells from human peripheral blood more effectively
killed CSCs in the presence of Cetuximab, as measured
using flow cytometry. When NK cells, and either Cetuxi-
mab or human IgG, were co-incubated with pancreatic
cancer cells at a 5:1 ratio, the presence of Cetuximab
resulted in a significantly (p <.001) lower proportion of
CSCs remaining after 48 hours, compared to IgG controls
(4.22% vs. 14%). Lastly we demonstrate that the combina-
tion of local radiation, ex vivo IL-2 activated NK cells, and
Cetuximab leads to potent anti-tumor effects against
subcutaneous human pancreatic tumor xenografts in vivo.
Primary tumor growth, as measured by external caliper,
was significantly delayed in the presence of Cetuximab,
compared to untreated animals, up to 28 days following
tumor implant (p < .0001). These preclinical results sug-
gest that, alongside conventional cancer therapies such as
local radiation, administering Cetuximab in combination
with NK cell based therapy could improve clinical strate-
gies to target CSCs and reduce the rate of tumor relapse.
Authors’ details
1Department of Dermatology, University of California, Davis Medical Center,
Sacramento, CA, USA. 2Department of Surgical Oncology, University of
California, Davis Medical Center, Sacramento, CA, USA. 3Department of
Radiation Oncology, University of California, Davis Medical Center,
Sacramento, CA, USA.
Published: 6 November 2014
doi:10.1186/2051-1426-2-S3-P13
Cite this article as: Grossenbacher et al.: Enhanced natural killer cell
targeting of cancer stem cells using Cetuximab. Journal for
ImmunoTherapy of Cancer 2014 2(Suppl 3):P13.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
1Department of Dermatology, University of California, Davis Medical Center,
Sacramento, CA, USA
Full list of author information is available at the end of the article
Grossenbacher et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P13
http://www.immunotherapyofcancer.org/content/2/S3/P13
© 2014 Grossenbacher et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
